| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | David P D Woldbye | |
| Tobias M Axelsen | |||
| P2860 | cites work | The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine | Q22252701 |
| Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease | Q22252880 | ||
| The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease | Q24338845 | ||
| An optogenetic toolbox designed for primates | Q24623252 | ||
| Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry | Q24630976 | ||
| Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis | Q24684263 | ||
| CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases | Q26747564 | ||
| Cardiac optogenetics | Q27014844 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| Alpha-synuclein in Lewy bodies | Q27860680 | ||
| The biology of VEGF and its receptors | Q27860704 | ||
| Spinal Plasticity and Behavior: BDNF-Induced Neuromodulation in Uninjured and Injured Spinal Cord | Q28072591 | ||
| Probing pain pathways with light | Q28074610 | ||
| Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 | Q28083357 | ||
| Parkinson Disease-linked Vps35 R524W Mutation Impairs the Endosomal Association of Retromer and Induces α-Synuclein Aggregation | Q28115384 | ||
| Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease | Q28187904 | ||
| The GDNF family: signalling, biological functions and therapeutic value | Q28216478 | ||
| Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor | Q28237467 | ||
| Optical deconstruction of parkinsonian neural circuitry | Q28238685 | ||
| Engineering GPCR signaling pathways with RASSLs | Q28289158 | ||
| Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial | Q28296434 | ||
| AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease | Q28304068 | ||
| AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial | Q28307713 | ||
| Signaling of glial cell line-derived neurotrophic factor and its receptor GFRα1 induce Nurr1 and Pitx3 to promote survival of grafted midbrain-derived neural stem cells in a rat model of Parkinson disease | Q28569094 | ||
| Dopamine neuron agenesis in Nurr1-deficient mice | Q28589034 | ||
| TFEB links autophagy to lysosomal biogenesis | Q29614835 | ||
| Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
| Association between early-onset Parkinson's disease and mutations in the parkin gene | Q29615733 | ||
| Pharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in a rat model of Parkinson's disease | Q30665304 | ||
| Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases | Q38113616 | ||
| The impact of the endoplasmic reticulum protein-folding environment on cancer development | Q38241996 | ||
| The medical treatment of Parkinson disease from James Parkinson to George Cotzias | Q38285816 | ||
| Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease | Q33201042 | ||
| Optogenetics | Q33576026 | ||
| Therapeutic potential of nerve growth factors in Parkinson's disease | Q33630577 | ||
| The on-off phenomenon | Q33631685 | ||
| Safety and tolerability of putaminal AADC gene therapy for Parkinson disease | Q33731687 | ||
| Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys | Q33819946 | ||
| The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice | Q33896035 | ||
| Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease | Q33903286 | ||
| Trk receptors: mediators of neurotrophin action | Q33950703 | ||
| Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus | Q33954181 | ||
| Brain-derived neurotrophic factor in neurodegenerative diseases | Q34017880 | ||
| Titer and product affect the distribution of gene expression after intraputaminal convection-enhanced delivery | Q34024890 | ||
| Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. | Q34039452 | ||
| Subthalamic GAD gene therapy in a Parkinson's disease rat model | Q34154186 | ||
| Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease | Q34186437 | ||
| MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons | Q34204195 | ||
| A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease | Q34209755 | ||
| Gene therapy for human genetic disease? | Q34227501 | ||
| Noninvasive optical inhibition with a red-shifted microbial rhodopsin | Q34285179 | ||
| Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. | Q34397099 | ||
| The DnaJ-domain protein RME-8 functions in endosomal trafficking. | Q34453151 | ||
| The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis | Q34498133 | ||
| Lewy body dementias. | Q34502646 | ||
| The genetic background of Parkinson's disease: current progress and future prospects | Q34513714 | ||
| Effects of transient focal inactivation of the basal ganglia in parkinsonian primates. | Q34520311 | ||
| Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial | Q34640765 | ||
| Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. | Q34646166 | ||
| Results from a phase I safety trial of hAADC gene therapy for Parkinson disease | Q34656075 | ||
| Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons | Q38330872 | ||
| Intracerebral injections of DNA nanoparticles encoding for a therapeutic gene provide partial neuroprotection in an animal model of neurodegeneration. | Q38698499 | ||
| Long-term protective effects of AAV9-mesencephalic astrocyte-derived neurotrophic factor gene transfer in parkinsonian rats | Q38718981 | ||
| Exploring the potential of genome editing CRISPR-Cas9 technology | Q38796245 | ||
| Optogenetic Approaches for Controlling Seizure Activity. | Q38834011 | ||
| Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects | Q38834545 | ||
| Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease | Q38839079 | ||
| Optogenetic Inhibition of the Subthalamic Nucleus Reduces Levodopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease. | Q38897142 | ||
| Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential. | Q38899748 | ||
| Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases | Q38909412 | ||
| Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease | Q38942851 | ||
| Leucine-rich repeat kinase 2 and Parkinson's disease | Q38977031 | ||
| Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies | Q39021688 | ||
| Optogenetic inactivation of the subthalamic nucleus improves forelimb akinesia in a rat model of Parkinson disease. | Q39264201 | ||
| Chemogenetic Modulation of G Protein-Coupled Receptor Signalling in Visual Attention Research. | Q39369789 | ||
| AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model | Q39402760 | ||
| Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. | Q39495044 | ||
| GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease | Q39516461 | ||
| Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease | Q39518245 | ||
| Pathogenic lysosomal depletion in Parkinson's disease | Q39655523 | ||
| Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. | Q39782948 | ||
| Teaching neurons to respond to placebos | Q40009826 | ||
| MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. | Q40095787 | ||
| Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors | Q40118732 | ||
| Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease | Q40197232 | ||
| Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease | Q40299515 | ||
| Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease | Q40326219 | ||
| Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease | Q40369273 | ||
| Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats | Q40380857 | ||
| Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson's Disease (PD). | Q40406909 | ||
| Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. | Q40466228 | ||
| Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). | Q40613492 | ||
| ??? | Q64821040 | ||
| Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer | Q34943604 | ||
| An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson's disease. | Q35057159 | ||
| Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. | Q35081561 | ||
| Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson's disease | Q35878528 | ||
| Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease | Q35932749 | ||
| The potential role of vascular endothelial growth factor in the central nervous system | Q35939261 | ||
| Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease | Q36085361 | ||
| NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease | Q36089698 | ||
| Mesencephalic astrocyte-derived neurotrophic factor protects the heart from ischemic damage and is selectively secreted upon sarco/endoplasmic reticulum calcium depletion | Q36122111 | ||
| Anhedonia and the brain reward circuitry in depression | Q36224442 | ||
| Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease | Q36288717 | ||
| Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism | Q36424540 | ||
| DREADDs for Neuroscientists | Q36595793 | ||
| Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease | Q36713101 | ||
| Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. | Q36722978 | ||
| Nurr1-Based Therapies for Parkinson's Disease. | Q36803630 | ||
| TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity | Q36835587 | ||
| Decreased NURR1 gene expression in patients with Parkinson's disease | Q36947424 | ||
| Correction of a Rat Model of Parkinson's Disease by Coexpression of Tyrosine Hydroxylase and Aromatic Amino Acid Decarboxylase from a Helper Virus-Free Herpes Simplex Virus Type 1 Vector | Q36969304 | ||
| Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease | Q36969309 | ||
| Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behaviora | Q36969314 | ||
| Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients | Q37027502 | ||
| Novel designer receptors to probe GPCR signaling and physiology | Q37136546 | ||
| Human striatal recordings reveal abnormal discharge of projection neurons in Parkinson's disease. | Q37213655 | ||
| A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys | Q37300994 | ||
| Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys | Q37301013 | ||
| Control of basal ganglia output by direct and indirect pathway projection neurons. | Q37325384 | ||
| Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys | Q37399627 | ||
| Glial cell line-derived neurotrophic factor partially ameliorates motor symptoms without slowing neurodegeneration in mice with respiratory chain-deficient dopamine neurons. | Q37466357 | ||
| Early Insights from Commercialization of Gene Therapies in Europe | Q37676260 | ||
| α-Synuclein and dopamine at the crossroads of Parkinson's disease | Q37801701 | ||
| The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease | Q37820210 | ||
| Viral vectors for gene delivery to the central nervous system | Q37946113 | ||
| Multifaces of neuropeptide Y in the brain--neuroprotection, neurogenesis and neuroinflammation | Q38057014 | ||
| An ERcentric view of Parkinson's disease | Q38076982 | ||
| Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects | Q40651049 | ||
| Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys | Q40695369 | ||
| Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys | Q40702469 | ||
| Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease | Q40710921 | ||
| Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. | Q40723341 | ||
| Adeno-associated virus vector-mediated triple gene transfer of dopamine synthetic enzymes | Q40756748 | ||
| Quantitative analysis of transgene protein, mRNA, and vector DNA following injection of an adenoviral vector harboring glial cell line-derived neurotrophic factor into the primate caudate nucleus | Q40822484 | ||
| Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease | Q40846012 | ||
| Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease | Q40861090 | ||
| Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach | Q40870377 | ||
| Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors | Q40988268 | ||
| Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial | Q41681737 | ||
| Optogenetic stimulation of cortico-subthalamic projections is sufficient to ameliorate bradykinesia in 6-ohda lesioned mice. | Q42051117 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. | Q42437200 | ||
| Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. | Q42502571 | ||
| Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial | Q42650874 | ||
| Role of two sequence motifs of mesencephalic astrocyte-derived neurotrophic factor in its survival-promoting activity. | Q43076952 | ||
| Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. | Q43109280 | ||
| Simvastatin induces neuroprotection in 6-OHDA-lesioned PC12 via the PI3K/AKT/caspase 3 pathway and anti-inflammatory responses | Q43683966 | ||
| Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. | Q43707952 | ||
| Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes | Q43892747 | ||
| Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. | Q43940212 | ||
| Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex | Q44553274 | ||
| Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum | Q44631221 | ||
| Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation | Q45168491 | ||
| The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model | Q45303082 | ||
| Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. | Q45859568 | ||
| Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism | Q45859700 | ||
| Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. | Q45882831 | ||
| Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration | Q45888308 | ||
| In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector | Q45889326 | ||
| Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage | Q45939046 | ||
| Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle trans | Q46504121 | ||
| Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. | Q46533983 | ||
| CRISPR, the disruptor | Q46719862 | ||
| Effect of optogenetic modulation on entopeduncular input affects thalamic discharge and behavior in an AAV2-α-synuclein-induced hemiparkinson rat model. | Q47610751 | ||
| Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys | Q48197305 | ||
| Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra | Q48234153 | ||
| Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys | Q48325968 | ||
| DNAJC13 genetic variants in parkinsonism. | Q48457194 | ||
| Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease | Q48475900 | ||
| BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra | Q48767968 | ||
| Regulation of human GDNF gene expression in nigral dopaminergic neurons using a new doxycycline-regulated NTS-polyplex nanoparticle system. | Q50207396 | ||
| Surgical Treatment of Parkinson's Disease. | Q50883359 | ||
| Chinese scientists to pioneer first human CRISPR trial. | Q51227731 | ||
| Effects of Brain-derived Neurotrophic Factor on 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in Monkeys | Q58413253 | ||
| Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat | Q78571001 | ||
| Long-term effects of deep brain stimulation in Parkinson's disease | Q81260476 | ||
| Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys | Q82240782 | ||
| NRSF/REST neuronal deficient mice are more vulnerable to the neurotoxin MPTP | Q84528017 | ||
| Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease | Q87303987 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 2 | |
| P921 | main subject | gene therapy | Q213901 |
| Parkinson's disease | Q11085 | ||
| P304 | page(s) | 195-215 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Journal of Parkinson's disease | Q26842319 |
| P1476 | title | Gene Therapy for Parkinson's Disease, An Update. | |
| P478 | volume | 8 |
| Q101237517 | Applications of focused ultrasound in the brain: from thermoablation to drug delivery |
| Q92410336 | Neuronal Activation Stimulates Cytomegalovirus Promoter-Driven Transgene Expression |
| Q92103830 | Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1) |
| Q89792742 | Strategies for the Treatment of Parkinson's Disease: Beyond Dopamine |
| Q92453609 | The future of stem cell therapies for Parkinson disease |
| Q91866682 | Using Drosophila as a platform for drug discovery from natural products in Parkinson's disease |
Search more.